banner



Home  ›  How Much Calicum To Add To Blood For Edta Reversal

How Much Calicum To Add To Blood For Edta Reversal

Written By Monday, 13 June 2022 Add Comment Edit

Class of drugs

Antithrombotic agents
Drug grade
Coagulation Cascade and Major Classes of Anticoagulants.png

Coagulation Pour and Major Classes of Anticoagulants
Class identifiers
ATC code B01
External links
MeSH D00534-class
In Wikidata

Anticoagulants, normally known equally blood thinners, are chemic substances that preclude or reduce coagulation of blood, prolonging the clotting time.[1] Some of them occur naturally in claret-eating animals such as leeches and mosquitoes, where they assistance continue the bite surface area unclotted long enough for the beast to obtain some blood.[two] [3] Equally a class of medications, anticoagulants are used in therapy for thrombotic disorders.[four] Oral anticoagulants (OACs) are taken past many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals.[5] [vi] Some anticoagulants are used in medical equipment, such every bit sample tubes, blood transfusion bags, middle-lung machines, and dialysis equipment.[vii] [viii] One of the first anticoagulants, warfarin, was initially approved every bit a rodenticide.[9]

Anticoagulants are closely related to antiplatelet drugs and thrombolytic drugs past manipulating the diverse pathways of claret coagulation.[10] Specifically, antiplatelet drugs inhibit platelet aggregation (clumping together), whereas anticoagulants inhibit specific pathways of the coagulation cascade, which happens later the initial platelet assemblage just before the formation of fibrin and stable aggregated platelet products.[11] [12]

Mutual anticoagulants include warfarin and heparin.[xiii]

Medical uses [edit]

The utilize of anticoagulants is a conclusion based upon the risks and benefits of anticoagulation.[14] The biggest gamble of anticoagulation therapy is the increased risk of bleeding.[15] In otherwise healthy people, the increased take a chance of bleeding is minimal, simply those who have had recent surgery, cognitive aneurysms, and other conditions may have too great of risk of haemorrhage.[16] [17] Generally, the do good of anticoagulation is prevention of or reduction of progression of a thromboembolic disease.[18] Some indications for anticoagulant therapy that are known to take benefit from therapy include:

  • Atrial fibrillation — commonly forms an atrial appendage clot[nineteen]
  • Coronary artery affliction[xx]
  • Deep vein thrombosis — tin can lead to pulmonary embolism[21]
  • Ischemic stroke[22]
  • Hypercoagulable states (e.chiliad., Factor Five Leiden) — can lead to deep vein thrombosis[23]
  • Mechanical eye valves[24]
  • Myocardial infarction[25]
  • Pulmonary embolism[26]
  • Restenosis from stents[27]
  • Cardiopulmonary bypass (or any other surgeries requiring temporary aortic apoplexy)[28]
  • Heart failure[29]

In these cases, anticoagulation therapy can forbid formation of dangerous clots or preclude growth of clots.[30]

The decision to begin therapeutic anticoagulation often involves the use of multiple bleeding risk predictable event tools as non-invasive pre-test stratifications due to the potential for bleeds while on blood thinning agents.[15] Among these tools are HAS-BLED,[31] ATRIA,[32] HEMORR2HAGES,[33] and CHA2DS2-VASc.[34] The risk of bleeding using the aforementioned take chances assessment tools must then exist weighed against thrombotic risk in order to formally determine patient's overall do good in starting anticoagulation therapy.[35]

Agin effects [edit]

The most serious and common adverse side issue associated with anticoagulant are increased gamble of bleeding, both nonmajor and major bleeding events.[36] Take chances of bleeding is dependent on the class of anticoagulant agent used, patient's age, and pre-existing health weather. Warfarin has an estimated incidence of bleeding of 15-twenty% per year and life-threatening bleeding rate of 1-three% per year.[37] Newer non-vitamin 1000 adversary oral anticoagulants announced to have fewer life-threatening bleeding events compared to warfarin.[38] [39] Additionally, patients anile lxxx years or more may be especially susceptible to bleeding complications, with a rate of thirteen bleeds per 100 person-years.[twoscore] Bleeding risk is especially important to consider in patients with renal harm and NOAC therapy due to the fact that all NOACs, to some extent, are excreted past the kidneys.[41] Thus, patients with renal damage may exist at higher adventure of increased bleeding.[42]

In people with cancer, a systematic review has constitute warfarin had no result on death rate or the risk of blood clots.[43] Withal it did increase the adventure of major haemorrhage in 107 more people per thou population and minor bleeding in 167 more people in 1000 population.[43] Apixaban had no effect on mortality, recurrence of blood clots in claret vessels or major bleeding or pocket-size bleeding, nonetheless this finding comes only from one report.[43]

Nonhemorrhagic adverse events are less mutual than hemorrhagic adverse events simply should still be monitored closely.[38] Nonhemorrhagic adverse events of warfarin include skin necrosis, limb gangrene, and purple toe syndrome.[44] Peel necrosis and limb gangrene are near usually observed on the third to eighth mean solar day of therapy.[45] [46] The exact pathogenesis of pare necrosis and limb gangrene are not completely understood but are believed to be associated with warfarin's upshot on inhibiting product of protein C and poly peptide S.[47] [48] Imperial toe syndrome typically develops 3 to 8 weeks afterward initiation of warfarin therapy.[49] [50] Other adverse effects of warfarin are associated with depletion of vitamin Thousand, which can lead to inhibition of G1a proteins and growth arrest-specific gene 6, which can atomic number 82 to increased risk of arterial calcification and eye valve, peculiarly if too much Vitamin D is present.[51] [52] Warfarin's interference of G1a proteins have also been linked to abnormalities in fetal bone development in mothers who were treated with warfarin during pregnancy.[53] [54] Long-term warfarin and heparin usage have also been linked to osteoporosis.[55] [44]

Another potentially serious complexity associated with heparin apply is called heparin-induced thrombocytopenia (HIT).[56] There are two distinct types of Hitting one) allowed-mediated and 2) non-allowed mediated.[56] Immune-mediated HIT most ordinarily arises five to ten days afterwards exposure to heparin.[57] Pathogenesis of allowed-mediated HIT is believed to be caused past heparin-dependent immunoglobulin antibodies binding to platelet factor 4/heparin complexes on platelets, leading to wide spread platelet activation.[58]

Interactions [edit]

Foods and food supplements with claret-thinning effects include nattokinase, lumbrokinase, beer, bilberry, celery, cranberries, fish oil, garlic, ginger, ginkgo, ginseng, green tea, horse chestnut, licorice, niacin, onion, papaya, pomegranate, red clover, soybean, St. John's wort, turmeric, wheatgrass, and willow bawl.[59] [60] [61] Many herbal supplements take blood-thinning backdrop, such as danshen and feverfew.[62] Multivitamins that do not collaborate with clotting are available for patients on anticoagulants.[63]

Nonetheless, some foods and supplements encourage clotting.[64] These include alfalfa, avocado, cat's claw, coenzyme Q10, and night leafy greens such equally spinach.[65] [66] Excessive intake of aforementioned nutrient should exist avoided whilst taking anticoagulants or, if coagulability is being monitored, their intake should be kept approximately abiding so that anticoagulant dosage tin exist maintained at a level high enough to counteract this effect without fluctuations in coagulability.[67] [68]

Grapefruit interferes with some anticoagulant drugs, increasing the amount of time it takes for them to exist metabolized out of the torso, and then should be eaten with caution when on anticoagulant drugs.[69]

Anticoagulants are oft used to care for astute deep vein thrombosis.[70] [71] People using anticoagulants to treat this condition should avoid using bed rest as a complementary treatment because in that location are clinical benefits to continuing to walk and remaining mobile while using anticoagulants in this style.[72] Bed residual while using anticoagulants tin harm patients in circumstances in which it is not medically necessary.[72]

Types [edit]

A number of anticoagulants are available. The traditional ones (warfarin, other coumarins, and heparins) are in widespread use.[73] Since the 2000s, a number of agents have been introduced that are collectively referred to as direct acting oral anticoagulants (DOACs), novel oral anticoagulants (NOACs), or non-vitamin One thousand antagonist oral anticoagulants.[74] [75] [76] These agents include directly thrombin inhibitor (dabigatran) and factor Xa inhibitor (rivaroxaban, apixaban, betrixaban and edoxaban) and they have been shown to exist as adept or possibly better than the coumarins with less serious side furnishings.[77] The newer anticoagulants (NOACs/DOACs), are more expensive than the traditional ones and should exist used with care in patients with kidney problems.[78]

Coumarins (vitamin K antagonists) [edit]

These oral anticoagulants are derived from coumarin, which is institute in many plants. A prominent fellow member of this form is warfarin (Coumadin) and was found to be the dominant anticoagulant prescribed in a big multispecialty practise.[79] It takes at least 48 to 72 hours for the anticoagulant issue to develop. Where an immediate issue is required, heparin must be given concomitantly. These anticoagulants are used to treat patients with deep-vein thrombosis (DVT), pulmonary embolism (PE) and to prevent emboli in patients with atrial fibrillation (AF), and mechanical prosthetic heart valves. Other examples are acenocoumarol, phenprocoumon, atromentin, and phenindione.[ citation needed ]

The coumarins brodifacoum and difenacoum are used as rodenticides only are not used medically.

Heparin and derivative substances [edit]

Heparin is the most widely used intravenous clinical anticoagulant worldwide.[fourscore] Heparin is a naturally occurring glycosaminoglycan. At that place are iii major categories of heparin: unfractionated heparin (UFH), depression molecular weight heparin (LMWH), and ultra-low-molecular weight heparin (ULMWH).[81] Unfractionated heparin is usually derived from pig intestines and bovine lungs.[82] UFH binds to the enzyme inhibitor antithrombin Three (AT), causing a conformational change that results in its activation.[83] The activated AT then inactivates cistron Xa, thrombin, and other coagulation factors.[84] Heparin can be used in vivo (by injection), and as well in vitro to prevent blood or plasma clotting in or on medical devices. In venipuncture, Vacutainer brand blood collecting tubes containing heparin commonly accept a green cap.[ citation needed ]

Depression molecular weight heparin (LMWH) [edit]

Low molecular weight heparin (LMWH), is produced through a controlled depolymerization of unfractionated heparin.[81] LMWH exhibits higher anti-Xa/anti-IIa activeness ratio and is useful as it does not require monitoring of the APTT coagulation parameter and has fewer side effects.[81]

Synthetic pentasaccharide inhibitors of factor Xa [edit]

  • Fondaparinux is a synthetic carbohydrate composed of the five sugars (pentasaccharide) in heparin that bind to antithrombin. It is a smaller molecule than low molecular weight heparin.
  • Idraparinux
  • Idrabiotaparinux

Directly acting oral [edit]

The directly acting oral anticoagulants (DOACs) were introduced on and afterward 2008.[85] There are five DOACs currently on the market: dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban.[86] They were also previously referred to as "new/novel" and "non-vitamin K antagonist" oral anticoagulants (NOACs).[87]

Compared to warfarin, DOACs have a rapid onset activeness and relatively short half-lives; hence, they carry out their function more speedily and effectively and allow for drugs to rapidly reduce their anticoagulation effects.[88] Routine monitoring and dose adjustments of DOACs is less important than for warfarin, as they accept better predictable anticoagulation activity.[89] DOAC monitoring, including laboratory monitoring and a complete medication review, should generally be conducted before initiation of a DOAC, i-3 months afterward initiation, and then every 6-12 months later.[ninety]

Both DOACs and warfarin are equivalently effective but compared to warfarin, DOACs have fewer drug interactions, no known dietary interactions, wider therapeutic index, and take conventional dosing that does not require dose adjustments with abiding monitoring.[91] [89] However, there is presently no countermeasure for most DOACs, unlike for warfarin; nonetheless, the short half-lives of DOACs will permit their effects to swiftly recede. A reversal agent for dabigatran, idarucizumab, is currently available and canonical for use past the FDA. Rates of adherence to DOACs are only modestly college than adherence to warfarin among patients prescribed these drugs, and thus adherence to anticoagulation is often poor, despite hopes that DOACs would atomic number 82 to higher adherence rates.[92]

DOACs are significantly more than expensive than warfarin afterward taking into consideration the cost of frequent blood testing associated with warfarin.[90]

Direct gene Xa inhibitors [edit]

Drugs such every bit rivaroxaban, apixaban and edoxaban piece of work by inhibiting factor Xa directly (unlike the heparins and fondaparinux, which work via antithrombin activation). Too included in this category are betrixaban from Portola Pharmaceuticals, the discontinued darexaban (YM150) from Astellas, and, more recently, the discontinued letaxaban (TAK-442) from Takeda and eribaxaban (PD0348292) from Pfizer. Betrixaban is significant as it was, in 2018, the merely oral factor Xa inhibitor canonical by the FDA for utilize in acutely medically ill patients.[93] Darexaban evolution was discontinued in September 2011; in a trial for prevention of recurrences of myocardial infarction in addition to dual antiplatelet therapy (DAPT), the drug did not demonstrate effectiveness, and the risk of haemorrhage was increased by approximately 300%.[94] The development of letaxaban was discontinued for acute coronary syndrome in May 2011, following negative results from a Phase Two written report.[95]

Straight thrombin inhibitors [edit]

Another type of anticoagulant is the directly thrombin inhibitor.[96] Current members of this grade include the bivalent drugs hirudin, lepirudin, and bivalirudin; and the monovalent drugs argatroban and dabigatran. An oral direct thrombin inhibitor, ximelagatran (Exanta) was denied blessing past the Food and Drug Assistants (FDA) in September 2004[97] and was pulled from the marketplace entirely in February 2006 after reports of severe liver damage and heart attacks.[98] In November 2010, dabigatran Etexilate was canonical by the FDA to forbid thrombosis in atrial fibrillation.

Relevance to dental treatments [edit]

Equally in any invasive procedures, patients on anticoagulation therapy have increased adventure for bleeding and caution should be used along with local hemostatic methods to minimize bleeding risk during the operation as well every bit mail-operatively.[99] However, with regards to DOACs and invasive dental treatments, there has not been enough clinical evidence and experience to show any reliable adverse effects, relevance or interaction between these ii.[100] Further clinical prospective studies on DOACs are required to investigate the bleeding risk and haemostasis associated to surgical dental procedures.[101]

Recommendations of modifications to usage/dosage of DOACs prior to dental treatments are made based on the balance of the bleeding risk of each procedure and also the individual's bleeding own bleeding risks and renal functionality.[102] With low-bleeding-hazard dental procedures, it is recommended that DOACs be connected past the patient as per normal, then as to avert whatsoever increase in the risk of thromboembolic event.[103] [104] For dental procedures with a higher gamble of bleeding complications (i.eastward. complex extractions, adjacent extractions leading to a large wound, or more than iii extractions), the recommended practice is for the patient to miss or delay a dose of their DOAC earlier such procedures so equally to minimize the effect on haemorrhage risk.[105]

Antithrombin protein therapeutics [edit]

The antithrombin poly peptide itself is used as a protein therapeutic that can be purified from human plasma[106] or produced recombinantly (for example, Atryn, which is produced in the milk of genetically modified goats.[107] [108])

Antithrombin is approved past the FDA as an anticoagulant for the prevention of clots before, during, or after surgery or birthing in patients with hereditary antithrombin deficiency.[106] [108]

Other [edit]

Many other anticoagulants exist, for use in enquiry and development, diagnostics, or as drug candidates.

  • Batroxobin, a toxin from a snake venom, clots platelet-rich plasma without affecting platelet functions (lyses fibrinogen).
  • Hementin is an anticoagulant protease from the salivary glands of the giant Amazon leech, Haementeria ghilianii.
  • Vitamin E
  • Alcoholic-drink

Reversal agents [edit]

With the growing number of patients taking oral anticoagulation therapy, studies into reversal agents are gaining increasing involvement due to major bleeding events and need for urgent anticoagulant reversal therapy.[109] Reversal agents for warfarin are more widely studied and established guidelines for reversal exist, due to longer history of utilise of warfarin and the power to get a more authentic measurement of anticoagulation effect in a patient via measuring the INR (International Normalized Ratio).[110] In general, vitamin Grand is about ordinarily used in order to reverse the outcome of warfarin in non-urgent settings.[111] Yet, in urgent settings, or in settings with extremely high INR (INR >20), hemostatic reversal agents such as fresh frozen plasma (FFP), recombinant factor VIIa, and prothrombin circuitous concentrate (PCC) accept been utilized with proven efficacy.[112] Specifically with warfarin, four factor PCC (4F-PCC) has been shown to have superior safe and bloodshed benefits compared to FPP in lowering INR levels.[109]

Although specific antidotes and reversal agents for DOACs are not as widely studied, idarucizumab (for dabigatran) and andexanet alfa (for factor Xa inhibitor) take been used in clinical settings with varying efficacy.[87] Idarucizumab is a monoclonal antibody, approved by the US FDA in 2015, that reverses effect of dabigatran past bounden to both free and thrombin-bound dabigatran.[113] [114] Andexanet alfa is a recombinant modified human factor Xa decoy that reverses the event of factor Xa inhibitors by binding at the active sites of factor Xa inhibitor and making it catalytically inactive.[115] [116] Andexanet alfa was canonical by US FDA in 2018.[117] Some other drug chosen ciraparantag, a potential reversal agent for direct gene Xa inhibitors, is still under investigation.[118] Additionally, hemostatic reversal agents have besides been used with varying efficacy to contrary effects of DOACs.[119] [120]

Coagulation inhibitor measurement [edit]

A Bethesda unit (BU) is a mensurate of blood coagulation inhibitor activeness. It is the amount of inhibitor that will inactivate half of a coagulant during the incubation menstruum.[121] It is the standard measure used in the United States, and is so named because it was adopted every bit a standard at a conference in Bethesda, Maryland.[122]

Laboratory use [edit]

Laboratory instruments, blood transfusion numberless, and medical and surgical equipment will go chock-full up and become not-operational if blood is immune to clot. In addition, test tubes used for laboratory blood tests will take chemicals added to stop blood clotting. Apart from heparin, nearly of these chemicals piece of work past binding calcium ions, preventing the coagulation proteins from using them.

  • Ethylenediaminetetraacetic acrid (EDTA) strongly and irreversibly chelates (binds) calcium ions, preventing blood from clotting.
  • Citrate is in liquid course in the tube and is used for coagulation tests, likewise as in claret transfusion bags. Information technology binds the calcium, only not as strongly as EDTA. Correct proportion of this anticoagulant to blood is crucial because of the dilution, and it can be reversed with the addition of calcium. It can be in the form of sodium citrate or acid-citrate-dextrose.
  • Oxalate has a mechanism similar to that of citrate. It is the anticoagulant used in fluoride oxalate tubes used to determine glucose and lactate levels.

Dental considerations for long-term users [edit]

Dental practitioners play an of import office in the early detection of anticoagulant overdose through oral manifestations equally the patient doesn't evidence any symptoms. Dental treatment of patients taking anticoagulant or antiplatelet medication raises safety concerns in terms of the potential risk of bleeding complications following invasive dental procedures. Therefore, at that place comes the need for sure guidelines for the dental care of patients taking these drugs.

Detecting overdose

An overdose in anticoagulants usually occurs in people who have heart issues and need to take anticoagulants in a long term, in social club to reduce the risk of stroke from their loftier blood pressure.

An International Normalised Ratio (INR) exam would be recommended, to confirm the overdose so that the dosage can be adjusted to an acceptable standard. The INR test measures the fourth dimension taken for a clot to form in a blood sample, relative to a standard.

An INR value of 1 indicates a level of coagulation equivalent to that of an average patient not taking warfarin and values greater than 1 indicate a longer clotting time and thus a longer bleeding fourth dimension.

Assessing bleeding risk

There are 2 main parts to the assessment of bleeding risk:

  • Assessment of the likely risk of haemorrhage associated with the required dental procedure
  • Assessment of the patient's individual level bleeding run a risk

Managing bleeding hazard

A patient who is on anticoagulants or antiplatelet medications may undergo dental treatments which are unlikely to crusade bleeding such as local anaesthesia injection, basic gum charting, removal of plaque, calculus and stain above the gum level, direct or indirect fillings which are above the gingiva, root culvert handling, taking impression for denture or crown and plumbing fixtures or adjustment of orthodontic appliances.  For all these procedures, it is recommended for the dentist to treat the patient post-obit the normal standard process and taking care to avoid whatever bleeding.

For a patient who needs to undergo dental treatments which is more likely to crusade bleeding such equally simple tooth extractions (1-3 teeth with pocket-sized wound size), drainage of swelling within the mouth, periodontal charting, root planing,  direct or indirect filling which extends below the gingiva, circuitous filling, flap raising procedure, gingival recontouring and biopsies, the dentist needs to have actress precautions apart from the standard procedure. The recommendations[123] are as follows:

  • if the patient has some other medical condition or taking other medication that may increase bleeding risk, consult the patient'due south full general medical practitioner or specialist
  • if the patient is on a curt grade anticoagulant or antiplatelet therapy, delay non-urgent, invasive procedure, until the medication has been discontinued
  • plan treatment for early in the mean solar day and calendar week, where possible, to allow time for the management of prolonged bleeding or re-bleeding, if information technology occurs
  • perform the procedure as atraumatically as possible, use appropriate local measures and simply discharge patient once haemostasis has been confirmed
  • if travel time to emergency care is a business organisation, identify particular emphasis at the time of the initial handling on the use of measures to avert complications
  • advise the patient to accept paracetamol, unless contraindicated, for pain relief rather than NSAIDs such equally aspirin, ibuprofen, diclofenac or naproxen
  • provide the patient with written post-handling communication and emergency contact details
  • follow the specific recommendations and advice given for the management of patients taking the different anticoagulants or antiplatelet drugs

At that place is general understanding that in virtually cases, handling regimens with older anticoagulants (e.g., warfarin) and antiplatelet agents (e.g., clopidogrel, ticlopidine, prasugrel, ticagrelor, and/or aspirin) should non be altered before dental procedures. The risks of stopping or reducing these medication regimens (i.e., thromboembolism, stroke, myocardial infarction) far outweigh the consequences of prolonged bleeding, which can be controlled with local measures. In patients with other existing medical atmospheric condition that can increment the risk of prolonged bleeding later on dental handling or who are receiving other therapy that can increase bleeding chance, dental practitioners may wish to consult the patient's doc to determine whether care tin safely exist delivered in a master care part. Any suggested modification to the medication regimen prior to dental surgery should be done in consultation and on communication of the patient's physician.

On the footing of limited evidence, general consensus appears to be that in most patients who are receiving the newer direct-acting oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban, or edoxaban) and undergoing dental handling (in conjunction with usual local measures to control bleeding), no change to the anticoagulant regimen is required. In patients deemed to be at higher risk of bleeding (e.chiliad., patients with other medical conditions or undergoing more than all-encompassing procedures associated with college bleeding risk), consideration may be given, in consultation with and on advice of the patient'south physician, to postponing the timing of the daily dose of the anticoagulant until after the process; timing the dental intervention as late equally possible after terminal dose of anticoagulant; or temporarily interrupting drug therapy for 24 to 48 hours.

Research [edit]

A substantial number of compounds is being investigated for use as anticoagulants. The virtually promising ones act on the contact activation organisation (factor XIIa and factor XIa); information technology is anticipated that this may provide agents that foreclose thrombosis without conferring a risk of bleeding.[124]

As of November 2021[update], the direct factor XIa inhibitor milvexian is in Phase 2 clinical trials for the prevention of embolism afterwards surgery.[125]

Come across likewise [edit]

  • Hypercoagulability in pregnancy
  • CHADS2 score

References [edit]

  1. ^ "Anticoagulant medicines". nhs.uk. 2018-02-06. Retrieved 2020-01-23 .
  2. ^ Azzopardi EA, Whitaker IS, Rozen WM, Naderi N, Kon M (October 2011). "Chemical and mechanical alternatives to leech therapy: a systematic review and critical appraisal". Journal of Reconstructive Microsurgery. 27 (8): 481–half dozen. doi:10.1055/s-0031-1284233. PMID 21780018.
  3. ^ Ha YR, Oh SR, Seo ES, Kim BH, Lee DK, Lee SJ (Apr 2014). "Detection of heparin in the salivary gland and midgut of Aedes togoi". The Korean Journal of Parasitology. 52 (2): 183–8. doi:10.3347/kjp.2014.52.two.183. PMC4028456. PMID 24850962.
  4. ^ Yoo, Hugo Hb; Nunes-Nogueira, Vania Santos; Fortes Villas Boas, Paulo J. (7 February 2020). "Anticoagulant treatment for subsegmental pulmonary embolism". The Cochrane Database of Systematic Reviews. 2020 (2): CD010222. doi:10.1002/14651858.CD010222.pub4. ISSN 1469-493X. PMC7004894. PMID 32030721.
  5. ^ Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, et al. (2015-12-30). ten Cate H (ed.). "Comparing of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis". PLOS ONE. 10 (12): e0144856. Bibcode:2015PLoSO..1044856C. doi:10.1371/periodical.pone.0144856. PMC4696796. PMID 26716830.
  6. ^ Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH (July 2017). "Effectiveness and Safety of Non-vitamin 1000 Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses". Clinical Therapeutics. 39 (7): 1456–1478.e36. doi:10.1016/j.clinthera.2017.05.358. PMID 28668628.
  7. ^ Banfi One thousand, Salvagno GL, Lippi 1000 (2007-01-01). "The office of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes". Clinical Chemical science and Laboratory Medicine. 45 (five): 565–76. doi:10.1515/CCLM.2007.110. PMID 17484616. S2CID 23824484.
  8. ^ Dobrovolskaia MA, McNeil SE (May 2015). "Condom anticoagulation when heart and lungs are "on holiday"". Register of Translational Medicine. 3 (Suppl 1): S11. doi:10.3978/j.issn.2305-5839.2015.02.03. PMC4437941. PMID 26046056.
  9. ^ Pirmohamed M (November 2006). "Warfarin: almost sixty years quondam and still causing issues". British Journal of Clinical Pharmacology. 62 (5): 509–11. doi:10.1111/j.1365-2125.2006.02806.x. PMC1885167. PMID 17061959.
  10. ^ Patel, S.; Singh, R.; Preuss, C. 5.; Patel, North. (2020). "Warfarin". StatPearls. StatPearls Publishing. PMID 29261922. Retrieved 2020-01-23 .
  11. ^ Iqbal AM, Lopez RA, Hai O (2020). "Antiplatelet Medications". StatPearls. StatPearls Publishing. PMID 30725747. Retrieved 2020-01-23 .
  12. ^ Harter One thousand, Levine Chiliad, Henderson SO (January 2015). "Anticoagulation drug therapy: a review". The Western Journal of Emergency Medicine. 16 (one): 11–seven. doi:10.5811/westjem.2014.12.22933. PMC4307693. PMID 25671002.
  13. ^ Winslow R, Johnson A (2007-12-x). "Race Is on for the Next Blood Thinner". The Wall Street Journal. p. A12. Retrieved 2008-01-06 . ...in a market now dominated by one of the oldest mainstay pills in medicine: the claret thinner warfarin. At least five next-generation blood thinners are in advanced testing to treat or forestall potentially debilitating or life-threatening blood clots in surgery and heart patients. Outset candidates could accomplish the market in 2009.
  14. ^ Djulbegovic M, Lee AI (September 2018). "An Update on the "Novel" and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy". Clinics in Breast Medicine. 39 (3): 583–593. doi:10.1016/j.ccm.2018.04.010. PMID 30122182. S2CID 52039169.
  15. ^ a b Parks AL, Fang MC (July 2017). "Scoring Systems for Estimating the Adventure of Anticoagulant-Associated Haemorrhage". Seminars in Thrombosis and Hemostasis. 43 (5): 514–524. doi:10.1055/s-0037-1598061. PMID 28359135. S2CID 1981707.
  16. ^ Zhu X (February 2017). "The hemorrhage risk of condom external ventricular drain insertion in aneurysmal subarachnoid hemorrhage patients requiring endovascular aneurysm treatment: a systematic review and meta-analysis". Periodical of Neurosurgical Sciences. 61 (one): 53–63. doi:ten.23736/S0390-5616.16.03244-6. PMID 25963956.
  17. ^ Banerjee K, Poddar Thousand, Mick S, White J, Krishnaswamy A, Johnston D, et al. (Nov 2017). "Meta-Analysis of Usefulness of Anticoagulation After Transcatheter Aortic Valve Implantation". The American Journal of Cardiology. 120 (9): 1612–1617. doi:10.1016/j.amjcard.2017.07.059. PMID 28844512.
  18. ^ "Blood Thinners". medlineplus.gov . Retrieved 2020-01-23 .
  19. ^ Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M (July 2015). "Efficacy and Harms of Straight Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis". Circulation. 132 (three): 194–204. doi:ten.1161/CIRCULATIONAHA.114.013267. PMC4765082. PMID 25995317.
  20. ^ Moustafa A, Ruzieh Chiliad, Eltahawy E, Karim S (2019). "Antithrombotic therapy in patients with atrial fibrillation and coronary artery affliction". Avicenna Journal of Medicine. 9 (4): 123–128. doi:10.4103/ajm.AJM_73_19. PMC6796304. PMID 31903386.
  21. ^ Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. (Feb 2016). "Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report". Chest. 149 (2): 315–352. doi:10.1016/j.chest.2015.xi.026. PMID 26867832.
  22. ^ Kapil N, Datta YH, Alakbarova N, Bershad E, Selim M, Liebeskind DS, et al. (May 2017). "Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke". Clinical and Applied Thrombosis/Hemostasis. 23 (iv): 301–318. doi:10.1177/1076029616660762. PMID 27461564. S2CID 43296498.
  23. ^ Skelley JW, White CW, Thomason AR (Jan 2017). "The utilise of direct oral anticoagulants in inherited thrombophilia". Periodical of Thrombosis and Thrombolysis. 43 (1): 24–30. doi:10.1007/s11239-016-1428-ii. PMID 27734187. S2CID 24650202.
  24. ^ Poli D, Antonucci Eastward, Pengo 5, Migliaccio L, Testa South, Lodigiani C, et al. (September 2018). "Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study". International Periodical of Cardiology. 267: 68–73. doi:10.1016/j.ijcard.2018.04.042. PMID 29957264. S2CID 49588203.
  25. ^ Almony GT, Lefkovits J, Topol EJ (May 1996). "Antiplatelet and anticoagulant use afterwards myocardial infarction". Clinical Cardiology. 19 (five): 357–65. doi:x.1002/clc.4960190506. PMID 8723593. S2CID 103327.
  26. ^ Konstantinides SV, Barco S, Lankeit M, Meyer One thousand (March 2016). "Management of Pulmonary Embolism: An Update". Journal of the American College of Cardiology. 67 (8): 976–xc. doi:x.1016/j.jacc.2015.xi.061. PMID 26916489.
  27. ^ Dong Z, Zheng J (September 2017). "Anticoagulation after coronary stenting: a systemic review". British Medical Bulletin. 123 (1): 79–89. doi:10.1093/bmb/ldx018. PMID 28910988. S2CID 3800129.
  28. ^ Lander H, Zammert M, FitzGerald D (September 2016). "Anticoagulation management during cantankerous-clamping and bypass". Best Practice & Research. Clinical Anaesthesiology. xxx (3): 359–lxx. doi:x.1016/j.bpa.2016.07.002. PMID 27650345.
  29. ^ Thomas, Isac; EncisoSilva, Jorge; Schlueter, Michelle; Greenberg, Barry (2016), Bauersachs, Johann; Butler, Javed; Sandner, Peter (eds.), "Anticoagulation Therapy and NOACs in Center Failure", Centre Failure, Springer International Publishing, vol. 243, pp. 515–535, doi:10.1007/164_2016_126, ISBN978-3-319-59658-7, PMID 28233177
  30. ^ Raschi Eastward, Bianchin Thousand, De Ponti R, De Ponti F, Ageno W (June 2017). "Emerging therapeutic uses of directly-interim oral anticoagulants: An evidence-based perspective". Pharmacological Research. 120: 206–218. doi:x.1016/j.phrs.2017.03.026. PMID 28366835. S2CID 36716760.
  31. ^ "HAS-BLED Score for Major Bleeding risk". MDCalc. Retrieved 2014-08-15 .
  32. ^ "ATRIA Bleeding Risk". MDCalc. Retrieved 2014-08-15 .
  33. ^ "HEMORR₂HAGES Score for Major Bleeding Risk". MDCalc . Retrieved 2020-01-23 .
  34. ^ "CHA2DS2-VASc". MDCalc. Retrieved 2014-08-15 .
  35. ^ Zhu Due west, He W, Guo L, Wang X, Hong K (September 2015). "The HAS-BLED Score for Predicting Major Haemorrhage Gamble in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis". Clinical Cardiology. 38 (nine): 555–61. doi:10.1002/clc.22435. PMC6490831. PMID 26418409.
  36. ^ Yee J, Kaide CG (August 2019). "Emergency Reversal of Anticoagulation". The Western Journal of Emergency Medicine. xx (5): 770–783. doi:x.5811/westjem.2018.five.38235. PMC6754204. PMID 31539334.
  37. ^ Zareh M, Davis A, Henderson S (November 2011). "Reversal of warfarin-induced hemorrhage in the emergency department". The Western Journal of Emergency Medicine. 12 (4): 386–92. doi:10.5811/westjem.2011.three.2051. PMC3236169. PMID 22224125.
  38. ^ a b Ageno Westward, Donadini M (November 2018). "Breadth of complications of long-term oral anticoagulant care". Hematology. American Society of Hematology. Instruction Program. 2018 (1): 432–438. doi:x.1182/asheducation-2018.ane.432. PMC6245998. PMID 30504343.
  39. ^ Ageno W, Mantovani LG, Haas Due south, Kreutz R, Monje D, Schneider J, et al. (January 2016). "Safe and effectiveness of oral rivaroxaban versus standard anticoagulation for the handling of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study". The Lancet. Haematology. 3 (1): e12-21. doi:x.1016/S2352-3026(xv)00257-4. PMID 26765643.
  40. ^ Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan Southward (May 2007). "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation". Circulation. 115 (21): 2689–96. doi:x.1161/CIRCULATIONAHA.106.653048. PMID 17515465. S2CID 8881388.
  41. ^ Turpie AG, Purdham D, Ciaccia A (September 2017). "Nonvitamin K antagonist oral anticoagulant use in patients with renal harm". Therapeutic Advances in Cardiovascular Disease. 11 (ix): 243–256. doi:x.1177/1753944717714921. PMC5562140. PMID 28651452.
  42. ^ Weir MR, Kreutz R (October 2018). "Influence of Renal Office on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Rubber of Not-Vitamin G Antagonist Oral Anticoagulants". Mayo Clinic Proceedings. 93 (x): 1503–1519. doi:10.1016/j.mayocp.2018.06.018. PMID 30286834. S2CID 52922296.
  43. ^ a b c Kahale, Lara A; Hakoum, Maram B; Tsolakian, Ibrahim 1000; Matar, Charbel F; Barba, Maddalena; Yosuico, Victor ED; Terrenato, Irene; Sperati, Francesca; Schünemann, Holger; Akl, Elie A (2017-12-29). "Oral anticoagulation in people with cancer who accept no therapeutic or condom indication for anticoagulation". Cochrane Database of Systematic Reviews. 12: CD006466. doi:10.1002/14651858.cd006466.pub6. ISSN 1465-1858. PMC6389337. PMID 29285754.
  44. ^ a b Ageno Westward, Gallus AS, Wittkowsky A, Crowther Thou, Hylek EM, Palareti G (February 2012). "Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e44S–e88S. doi:10.1378/chest.11-2292. PMC3278051. PMID 22315269.
  45. ^ Verhagen H (2009-04-24). "Local haemorrhage and necrosis of the skin and underlying tissues, during anti-coagulant therapy with dicumarol or dicumacyl". Acta Medica Scandinavica. 148 (half dozen): 453–67. doi:10.1111/j.0954-6820.1954.tb01741.10. PMID 13171021.
  46. ^ Weinberg Ac, Lieskovsky G, McGehee WG, Skinner DG (August 1983). "Warfarin necrosis of the skin and subcutaneous tissue of the male external ballocks". The Periodical of Urology. 130 (2): 352–four. doi:ten.1016/S0022-5347(17)51147-7. PMID 6876290.
  47. ^ Broekmans AW, Bertina RM, Loeliger EA, Hofmann V, Klingemann HG (June 1983). "Protein C and the development of pare necrosis during anticoagulant therapy". Thrombosis and Haemostasis. 49 (3): 251. doi:10.1055/s-0038-1657378. PMID 6688309.
  48. ^ Grimaudo V, Gueissaz F, Hauert J, Sarraj A, Kruithof EK, Bachmann F (January 1989). "Necrosis of skin induced by coumarin in a patient scarce in poly peptide S". BMJ. 298 (6668): 233–iv. doi:ten.1136/bmj.298.6668.233. PMC1835547. PMID 2522326.
  49. ^ Talmadge DB, Spyropoulos Air conditioning (May 2003). "Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome". Pharmacotherapy. 23 (v): 674–7. doi:10.1592/phco.23.five.674.32200. PMID 12741443. S2CID 28632135.
  50. ^ Raj K, Collins B, Rangarajan S (September 2001). "Purple toe syndrome post-obit anticoagulant therapy". British Journal of Haematology. 114 (four): 740. doi:10.1046/j.1365-2141.2001.03107.x. PMID 11564060. S2CID 20482173.
  51. ^ Adams J, Pepping J (August 2005). "Vitamin M in the treatment and prevention of osteoporosis and arterial calcification" (PDF). American Journal of Wellness-System Chemist's shop. 62 (15): 1574–81. doi:ten.2146/ajhp040357. PMID 16030366.
  52. ^ Danziger J (September 2008). "Vitamin K-dependent proteins, warfarin, and vascular calcification". Clinical Periodical of the American Social club of Nephrology. three (5): 1504–10. doi:10.2215/CJN.00770208. PMC4571144. PMID 18495950.
  53. ^ Pettifor JM, Benson R (March 1975). "Congenital malformations associated with the administration of oral anticoagulants during pregnancy". The Journal of Pediatrics. 86 (3): 459–62. doi:10.1016/S0022-3476(75)80986-three. PMID 1113236.
  54. ^ Hall JG, Pauli RM, Wilson KM (January 1980). "Maternal and fetal sequelae of anticoagulation during pregnancy". The American Periodical of Medicine. 68 (1): 122–40. doi:10.1016/0002-9343(80)90181-3. PMID 6985765.
  55. ^ Cuff BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF (January 2006). "Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2". Archives of Internal Medicine. 166 (2): 241–6. doi:10.1001/archinte.166.2.241. PMID 16432096.
  56. ^ a b Baroletti SA, Goldhaber SZ (Baronial 2006). "Heparin-induced thrombocytopenia". Circulation. 114 (8): e355-6. doi:ten.1161/CIRCULATIONAHA.106.632653. PMID 16923760.
  57. ^ Warkentin TE, Greinacher A, Koster A, Lincoff AM (June 2008). "Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Show-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 340S–380S. doi:10.1378/chest.08-0677. PMID 18574270.
  58. ^ Linkins LA, Hu G, Warkentin TE (October 2018). "Systematic review of fondaparinux for heparin-induced thrombocytopenia: When in that location are no randomized controlled trials". Research and Practice in Thrombosis and Haemostasis. two (4): 678–683. doi:10.1002/rth2.12145. PMC6178656. PMID 30349886.
  59. ^ Wittkowsky AK (September 2001). "Drug interactions update: drugs, herbs, and oral anticoagulation". Journal of Thrombosis and Thrombolysis. 12 (1): 67–71. doi:ten.1023/A:1012742628628. PMID 11711691. S2CID 22447084.
  60. ^ Rui, Tian-Qi; Zhang, Liang; Qiao, Hong-Zhi; Huang, Ping; Qian, Shuai; Li, Jun-Song; Chen, Zhi-Peng; Fu, Ting-Ming; Di, Liu-Qing; Cai, Baochang (January 2016). "Training and Physicochemical and Pharmacokinetic Characterization of Ginkgo Lactone Nanosuspensions for Antiplatelet Assemblage". Journal of Pharmaceutical Sciences. 105 (1): 242–249. doi:10.1016/j.xphs.2015.x.002. PMID 26852855.
  61. ^ Yun, Yeo-Pyo; Practice, Jae-Ho; Ko, Sung-Ryong; Ryu, Shi-Yong; Kim, Jung-Hyo; Vocal, Ho-Cheol; Park, Young-Doo; Ahn, Kyoo-Seok; Kim, Sung-Hoon (October 2001). "Effects of Korean ruby ginseng and its mixed prescription on the high molecular weight dextran-induced claret stasis in rats and human platelet aggregation". Periodical of Ethnopharmacology. 77 (2–3): 259–264. doi:ten.1016/S0378-8741(01)00303-8. PMID 11535373.
  62. ^ Choi, Songie; Oh, Dal-Seok; Jerng, Ui Min (2017-08-ten). Borrelli, Francesca (ed.). "A systematic review of the pharmacokinetic and pharmacodynamic interactions of herbal medicine with warfarin". PLOS ONE. 12 (eight): e0182794. Bibcode:2017PLoSO..1282794C. doi:x.1371/journal.pone.0182794. ISSN 1932-6203. PMC5552262. PMID 28797065.
  63. ^ Kurnik, Daniel; Lubetsky, Aharon; Loebstein, Ronen; Almog, Shlomo; Halkin, Hillel (November 2003). "Multivitamin Supplements May Touch Warfarin Anticoagulation in Susceptible Patients". Annals of Pharmacotherapy. 37 (11): 1603–1606. doi:x.1345/aph.1D102. ISSN 1060-0280. PMID 14565795. S2CID 43777757.
  64. ^ Harder, Sebastian; Thürmann, Petra (June 1996). "Clinically Of import Drug Interactions with Anticoagulants: An Update". Clinical Pharmacokinetics. thirty (six): 416–444. doi:10.2165/00003088-199630060-00002. ISSN 0312-5963. PMID 8792056. S2CID 22389544.
  65. ^ Lippi, Giuseppe; Mattiuzzi, Camilla; Franchini, Massimo (April 2016). "Vegetables intake and venous thromboembolism: a systematic review". Claret Coagulation & Fibrinolysis. 27 (iii): 242–245. doi:10.1097/MBC.0000000000000427. ISSN 0957-5235. PMID 27023878. S2CID 33380206.
  66. ^ "Avocado: Health Benefits, Uses, Side Effects, Dosage & Interactions". RxList . Retrieved 2020-01-23 .
  67. ^ Dentali, Francesco; Crowther, Mark; Galli, Matteo; Pomero, Fulvio; Garcia, David; Clark, Nathan; Spadafora, Laura; Witt, Daniel; Ageno, Walter; for the WARPED Investigators (2016-05-27). "Effect of Vitamin K Intake on the Stability of Handling with Vitamin K Antagonists: A Systematic Review of the Literature". Seminars in Thrombosis and Hemostasis. 42 (half-dozen): 671–681. doi:ten.1055/south-0036-1581105. ISSN 0094-6176. PMID 27232386.
  68. ^ "Warfarin Uses, Dosage, Side Effects". Drugs.com . Retrieved 2020-01-23 .
  69. ^ Sullivan, Dawn Chiliad.; Ford, Marjorie A.; Boyden, Thomas W. (1998-08-01). "Grapefruit juice and the response to warfarin". American Journal of Health-Organization Pharmacy. 55 (15): 1581–1583. doi:10.1093/ajhp/55.fifteen.1581. ISSN 1079-2082. PMID 9706183.
  70. ^ Di Nisio, Marcello; van Es, Nick; Büller, Harry R (December 2016). "Deep vein thrombosis and pulmonary embolism". The Lancet. 388 (10063): 3060–3073. doi:10.1016/S0140-6736(16)30514-1. PMID 27375038. S2CID 25712161.
  71. ^ Koehl, Jennifer L; Hayes, Bryan D.; Al‐Samkari, Hanny; Rosovsky, Rachel (2020-01-23). "A comprehensive evaluation of apixaban in the treatment of venous thromboembolism". Expert Review of Hematology. xiii (2): 155–173. doi:ten.1080/17474086.2020.1711731. ISSN 1747-4086. PMID 31958251. S2CID 210842354.
  72. ^ a b American Physical Therapy Clan (15 September 2014), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Physical Therapy Association, retrieved xv September 2014 , which cites
    • Aissaoui Due north, Martins E, Mouly S, Weber S, Meune C (September 2009). "A meta-assay of bed residuum versus early ambulation in the management of pulmonary embolism, deep vein thrombosis, or both". International Journal of Cardiology. 137 (1): 37–41. doi:10.1016/j.ijcard.2008.06.020. PMID 18691773.
    • Anderson CM, Overend TJ, Godwin J, Sealy C, Sunderji A (2009). "Ambulation afterwards deep vein thrombosis: a systematic review". Physiotherapy Canada. 61 (three): 133–40. doi:ten.3138/physio.61.3.133. PMC2787576. PMID 20514175.
  73. ^ Di Minno, Alessandro; Frigerio, Beatrice; Spadarella, Gaia; Ravani, Alessio; Sansaro, Daniela; Amato, Mauro; Kitzmiller, Joseph P.; Pepi, Mauro; Tremoli, Elena; Baldassarre, Damiano (July 2017). "Old and new oral anticoagulants: Nutrient, herbal medicines and drug interactions". Blood Reviews. 31 (4): 193–203. doi:10.1016/j.blre.2017.02.001. PMID 28196633.
  74. ^ Verdecchia, Paolo; Angeli, Fabio; Aita, Adolfo; Bartolini, Claudia; Reboldi, Gianpaolo (April 2016). "Why switch from warfarin to NOACs?". Internal and Emergency Medicine. xi (3): 289–293. doi:10.1007/s11739-016-1411-0. ISSN 1828-0447. PMID 26972708. S2CID 25807727.
  75. ^ Diener, Hans-Christoph; Ntaios, George; O'Donnell, Martin; Easton, J. Donald (2018-09-22). "Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke". Skilful Opinion on Pharmacotherapy. xix (14): 1597–1602. doi:10.1080/14656566.2018.1515913. ISSN 1465-6566. PMID 30152249. S2CID 52099757.
  76. ^ Pol, Derk; Curtis, Claire; Ramkumar, Satish; Bittinger, Logan (April 2019). "NOACs At present Mainstream for the Utilise of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia". Heart, Lung and Circulation. 28 (4): e40–e42. doi:10.1016/j.hlc.2018.03.010. PMID 29861320. S2CID 44103560.
  77. ^ Werdan K, Braun-Dullaeus R, Presek P (August 2013). "Anticoagulation in atrial fibrillation: NOAC'south the word". Deutsches Ärzteblatt International. 110 (31–32): 523–4. doi:x.3238/arztebl.2013.0523. PMC3782018. PMID 24069072. Things have inverse dramatically with the introduction of the new oral anticoagulants (NOACs) — dabigatran, a factor IIa (thrombin) inhibitor, and the factor Xa inhibitors rivaroxaban and apixaban. Clinical trials take shown them therapeutically superior, or at to the lowest degree non-inferior, to VKAs, with less serious side effects.
  78. ^ Heine, Gunnar H.; Brandenburg, Vincent; Schirmer, Stephan H. (2018-04-27). "Orale Antikoagulation bei chronischer Nierenerkrankung und Vorhofflimmern". Deutsches Ärzteblatt Online. 115 (17): 287–294. doi:x.3238/arztebl.2018.0287. ISSN 1866-0452. PMC5974258. PMID 29789105.
  79. ^ Efird LE, Chasler J, Alexander GC, McGuire M (Jun 21, 2016). "Prescribing Patterns of Novel Anticoagulants Within a Statewide Multispecialty Practice". American Journal of Pharmacy Benefits. 8 (3): 97–102.
  80. ^ Linhardt RJ (June 2003). "2003 Claude S. Hudson Honour address in carbohydrate chemistry. Heparin: construction and activity". Periodical of Medicinal Chemistry. 46 (13): 2551–64. doi:x.1021/jm030176m. PMID 12801218.
  81. ^ a b c Onishi A, St Ange Chiliad, Dordick JS, Linhardt RJ (June 2016). "Heparin and anticoagulation". Frontiers in Bioscience. 21 (7): 1372–92. doi:ten.2741/4462. PMID 27100512.
  82. ^ Casu B, Naggi A, Torri G (February 2015). "Re-visiting the structure of heparin". Saccharide Research. 403: 60–8. doi:x.1016/j.carres.2014.06.023. PMID 25088334.
  83. ^ Seo Y, Andaya A, Leary JA (March 2012). "Grooming, separation, and conformational assay of differentially sulfated heparin octasaccharide isomers using ion mobility mass spectrometry". Analytical Chemical science. 84 (5): 2416–23. doi:10.1021/ac203190k. PMC3296823. PMID 22283665.
  84. ^ Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A (April 2016). "Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis". Intensive Care Medicine. 42 (four): 505–520. doi:ten.1007/s00134-016-4225-7. PMC2137061. PMID 26862016.
  85. ^ "Human medicines European public assessment study (EPAR): Pradaxa, dabigatran etexilate, Arthroplasty, Replacement,Venous Thromboembolism, Date of authorisation: 17/03/2008, Revision: 29, Condition: Authorised". Instance Medical Research. 2019-07-16. doi:x.31525/cmr-1321569. ISSN 2643-4652. S2CID 241319098.
  86. ^ Douxfils J, Ageno Westward, Samama CM, Lessire Due south, Ten Cate H, Verhamme P, et al. (February 2018). "Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians". Journal of Thrombosis and Haemostasis. 16 (2): 209–219. doi:10.1111/jth.13912. PMID 29193737. S2CID 46865986.
  87. ^ a b Udayachalerm Southward, Rattanasiri S, Angkananard T, Attia J, Sansanayudh N, Thakkinstian A (September 2018). "The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis". Clinical and Applied Thrombosis/Hemostasis. 24 (9_suppl): 117S–126S. doi:10.1177/1076029618796339. PMC6714855. PMID 30176738.
  88. ^ "Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs" (PDF). Scottish Dental Clinical Effectiveness Plan. August 2015.
  89. ^ a b Clark NP (November 2018). "Office of the anticoagulant monitoring service in 2018: beyond warfarin". Hematology. American Society of Hematology. Education Programme. 2018 (ane): 348–352. doi:10.1182/asheducation-2018.i.348. PMC6246023. PMID 30504331.
  90. ^ a b Chen, Ashley; Stecker, Eric; A. Warden, Bruce (2020-06-fifteen). "Directly Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges". Journal of the American Center Clan: Cardiovascular and Cerebrovascular Illness. 9 (13): e017559. doi:10.1161/JAHA.120.017559. ISSN 2047-9980. PMC7670541. PMID 32538234.
  91. ^ "Novel anticoagulants". Heart Matters Magazine. British Heart Foundation.
  92. ^ Ozaki, Aya F.; Choi, Austin Due south.; Le, Quan T.; Ko, Dennis T.; Han, Janet 1000.; Park, Sandy S.; Jackevicius, Cynthia A. (2020). "Real-Globe Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis". Circulation: Cardiovascular Quality and Outcomes. xiii (iii): e005969. doi:10.1161/CIRCOUTCOMES.119.005969. ISSN 1941-7705. PMID 32148102. S2CID 212640015.
  93. ^ Lekura J, Kalus JS (August 2018). "Overview of betrixaban and its role in clinical practice". American Journal of Health-Arrangement Pharmacy. 75 (xv): 1095–1102. doi:x.2146/ajhp170785. PMID 29941506. S2CID 49418996.
  94. ^ Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, et al. (October 2011). "Blood-red-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome". European Heart Journal. 32 (xx): 2541–54. doi:10.1093/eurheartj/ehr334. PMC3295208. PMID 21878434.
  95. ^ Dwyer J, Walsh C (May 2013). "First Fourth dimension European Approval for Xarelto in ACS". Decision Resources. Archived from the original on 2014-07-19.
  96. ^ Di Nisio M, Middeldorp S, Büller HR (September 2005). "Direct thrombin inhibitors" (PDF). The New England Periodical of Medicine. 353 (10): 1028–40. doi:10.1056/NEJMra044440. PMID 16148288.
  97. ^ "Exanta". Ask Dr. Stephan Moll. The Thrombophilia Sensation Projection. Archived from the original on 25 May 2011.
  98. ^ "Exanta™ (ximelagatran) Report report summaries". AstraZeneca Clinical Trials. Archived from the original on 2006-03-eighteen.
  99. ^ Manfredi M, Dave B, Percudani D, Christoforou J, Karasneh J, Diz Dios P, et al. (June 2019). "World workshop on oral medicine Vii: Directly anticoagulant agents management for invasive oral procedures: A systematic review and meta-analysis". Oral Diseases. 25 Suppl 1 (S1): 157–173. doi:10.1111/odi.13086. PMID 31140701. S2CID 169034257.
  100. ^ Bensi C, Belli S, Paradiso D, Lomurno Thou (July 2018). "Postoperative bleeding risk of direct oral anticoagulants after oral surgery procedures: a systematic review and meta-assay". International Journal of Oral and Maxillofacial Surgery. 47 (7): 923–932. doi:10.1016/j.ijom.2018.03.016. PMID 29627150. S2CID 4697607.
  101. ^ Costantinides F, Rizzo R, Pascazio Fifty, Maglione Thou (January 2016). "Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications". BMC Oral Health. sixteen: 5. doi:10.1186/s12903-016-0170-7. PMC4731944. PMID 26822674.
  102. ^ Kosyfaki P, Att W, Strub JR (August 2011). "The dental patient on oral anticoagulant medication: a literature review". Periodical of Oral Rehabilitation. 38 (8): 615–33. doi:x.1111/j.1365-2842.2010.02184.ten. PMID 21073495.
  103. ^ van Diermen DE, van der Waal I, Hoogstraten J (December 2013). "Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants". Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 116 (6): 709–sixteen. doi:10.1016/j.oooo.2013.07.026. PMID 24120910.
  104. ^ Shi Q, Xu J, Zhang T, Zhang B, Liu H (2017-02-08). "Postal service-operative Haemorrhage Risk in Dental Surgery for Patients on Oral Anticoagulant Therapy: A Meta-analysis of Observational Studies". Frontiers in Pharmacology. 8: 58. doi:10.3389/fphar.2017.00058. PMC5296357. PMID 28228727.
  105. ^ "Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs: Dental Clinical Guidance" (PDF). Scottish Dental Clinical Effectiveness Program.
  106. ^ a b "Thrombate III label" (PDF). Archived from the original (PDF) on 2012-eleven-fifteen.
  107. ^ Center for Biologics Evaluation and Research (24 April 2019). "Fractionated Plasma Products - ATryn". www.fda.gov.
  108. ^ a b "Antithrombin (Recombinant) US Package Insert ATryn for Injection February 3, 2009" (PDF). Food and Drug Assistants.
  109. ^ a b Tornkvist, Max; Smith, J. Gustav; Labaf, Ashkan (February 2018). "Current bear witness of oral anticoagulant reversal: A systematic review". Thrombosis Research. 162: 22–31. doi:10.1016/j.thromres.2017.12.003. PMID 29258056.
  110. ^ Hanley, J P (2004-11-01). "Warfarin reversal". Journal of Clinical Pathology. 57 (eleven): 1132–1139. doi:10.1136/jcp.2003.008904. ISSN 0021-9746. PMC1770479. PMID 15509671.
  111. ^ Makris, M.; Greaves, M.; Phillips, W. South.; Kitchen, S.; Rosendaal, F. R.; Preston, Due east. F. (March 1997). "Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy". Thrombosis and Haemostasis. 77 (iii): 477–480. doi:ten.1055/s-0038-1655992. ISSN 0340-6245. PMID 9065997.
  112. ^ Chai-Adisaksopha, Chatree; Hillis, Christopher; Siegal, Deborah M.; Movilla, Ron; Heddle, Nancy; Iorio, Alfonso; Crowther, Mark (September 2016). "Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis". Thrombosis and Haemostasis. 116 (11): 879–890. doi:ten.1160/TH16-04-0266. ISSN 0340-6245. PMID 27488143.
  113. ^ Pakraftar, Sam (2014). "Dabigatran etixilate and traumatic brain injury: Evolving anticoagulants crave evolving care plans". World Periodical of Clinical Cases. two (eight): 362–6. doi:10.12998/wjcc.v2.i8.362. ISSN 2307-8960. PMC4133427. PMID 25133148.
  114. ^ Ryn, Joanne van; Stangier, Joachim; Haertter, Sebastian; Liesenfeld, Karl-Heinz; Wienen, Wolfgang; Feuring, Martin; Clemens, Andreas (2010). "Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Estimation of coagulation assays and reversal of anticoagulant activity". Thrombosis and Haemostasis. 103 (6): 1116–1127. doi:10.1160/TH09-11-0758. ISSN 0340-6245. PMID 20352166.
  115. ^ Siegal, Deborah 1000.; Curnutte, John T.; Connolly, Stuart J.; Lu, Genmin; Conley, Pamela B.; Wiens, Brian L.; Mathur, Vandana S.; Castillo, Janice; Bronson, Michele D.; Leeds, Janet M.; Mar, Florie A. (2015-12-17). "Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity". New England Journal of Medicine. 373 (25): 2413–2424. doi:10.1056/NEJMoa1510991. ISSN 0028-4793. PMID 26559317.
  116. ^ Connolly, Stuart J.; Milling, Truman J.; Eikelboom, John W.; Gibson, C. Michael; Curnutte, John T.; Gold, Alex; Bronson, Michele D.; Lu, Genmin; Conley, Pamela B.; Verhamme, Peter; Schmidt, Jeannot (2016-09-22). "Andexanet Alfa for Acute Major Bleeding Associated with Cistron Xa Inhibitors". New England Journal of Medicine. 375 (12): 1131–1141. doi:10.1056/NEJMoa1607887. ISSN 0028-4793. PMC5568772. PMID 27573206.
  117. ^ Reed, Mirembe; Tadi, Prasanna; Nicolas, Diala (2020), "Andexanet Alfa", StatPearls, StatPearls Publishing, PMID 30137783, retrieved 2020-01-23
  118. ^ Ansell, Jack Due east.; Bakhru, Sasha H.; Laulicht, Bryan E.; Steiner, Solomon Due south.; Grosso, Michael A.; Dark-brown, Karen; Dishy, Victor; Lanz, Hans J.; Mercuri, Michele F.; Noveck, Robert J.; Costin, James C. (February 2017). "Single-dose ciraparantag safely and completely reverses anticoagulant furnishings of edoxaban". Thrombosis and Haemostasis. 117 (2): 238–245. doi:10.1160/TH16-03-0224. ISSN 0340-6245. PMC6260118. PMID 27853809.
  119. ^ Eerenberg, Elise S.; Kamphuisen, Pieter Due west.; Sijpkens, Meertien K.; Meijers, Joost C.; Buller, Harry R.; Levi, Marcel (2011-ten-04). "Reversal of Rivaroxaban and Dabigatran past Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Report in Healthy Subjects". Apportionment. 124 (xiv): 1573–1579. doi:x.1161/CIRCULATIONAHA.111.029017. ISSN 0009-7322. PMID 21900088. S2CID 961167.
  120. ^ Marlu, Raphael; Hodaj, Enkelejda; Paris, Adeline; Albaladejo, Pierre; Crackowski, Jean; Pernod, Gilles (2012). "Result of non-specific reversal agents on anticoagulant activeness of dabigatran and rivaroxaban: A randomised crossover ex vivo study in healthy volunteers". Thrombosis and Haemostasis. 108 (8): 217–224. doi:x.1160/TH12-03-0179. ISSN 0340-6245. PMID 22627883.
  121. ^ "Bethesda unit". Biology Online . Retrieved 2009-02-14 .
  122. ^ Schumacher Hr (2000). Handbook of Hematologic Pathology. Informa Wellness Care. p. 583. ISBN978-0-8247-0170-3.
  123. ^ "Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs – New guidance from SDCEP | Scottish Dental". Retrieved 2020-02-xx .
  124. ^ Fredenburgh, James C; Weitz, Jeffrey I (12 October 2020). "New Anticoagulants: Moving Beyond the Direct Oral Anticoagulants". Periodical of Thrombosis and Haemostasis. 19 (ane): xx–29. doi:10.1111/jth.15126. PMID 33047462. S2CID 222320654.
  125. ^ Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. (Nov 2021). "Milvexian for the Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (23): 2161–2172. doi:10.1056/NEJMoa2113194. PMID 34780683. S2CID 244132392.

External links [edit]

  • Staying Active and Healthy with Blood Thinners by the Agency for Healthcare Research and Quality
  • New oral anticoagulants for stroke prevention in atrial fibrillation

How Much Calicum To Add To Blood For Edta Reversal,

Source: https://en.wikipedia.org/wiki/Anticoagulant

Posted by: palmerrecance.blogspot.com

0 Response to "How Much Calicum To Add To Blood For Edta Reversal"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel